IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT) today announced its unaudited financial and
operational results for the three and six month periods ended June 30, 2009.


Highlights:

- Company shows revenue increase over second quarter 2008.

- Positive clinical outcomes demonstrated for bioFILM PA

- Company maintains healthy cash reserve

"The Company has maintained its product development momentum through an increase
in contract revenue in the second quarter and continuing strong cash reserves"
say Dr. James Timourian, Chief Financial Officer of Innovotech. "bioFILM PA has
achieved another milestone with the demonstration of positive clinical outcomes
in use in cystic fibrosis patients (see www.innovotech.ca for more detail).
Agress continues to show promise in an expanding portfolio of crop and disease
uses while awaiting regulatory approval. Evaluation and licensing discussion
have continued with several multinational agriculture companies."




Financial Summary

----------------------------------------------------------------------------
                    Three-month    Three-month     Six- month    Six- month
                   period ended   period ended   period ended  period ended
                        June 30,       June 30,       June 30,      June 30,
                           2009           2008           2009          2008
----------------------------------------------------------------------------

Revenues                373,697        289,989        589,698       718,275
----------------------------------------------------------------------------

G&A                     251,096        204,040        497,132       445,816
----------------------------------------------------------------------------

R&D                     208,857        164,374        401,007       267,780
----------------------------------------------------------------------------

Net income (loss)      (287,551)      (216,886)      (654,820)     (313,611)
----------------------------------------------------------------------------

Cash Reserves                                       1,773,452     1,998,776
----------------------------------------------------------------------------



About Innovotech Inc:

Innovotech is a product development company focusing on the development of
solutions to medical, agricultural and industrial problems caused by microbial
biofilms. Biofilms are protected communities of microorganisms which are very
common and very difficult to treat due to their inherent resistance. The company
currently has two products in advanced stages of development: bioFILM PA is a
diagnostic kit which assists physicians in the selection of the most effective
antibiotic treatment of patients with chronic lung infections. AgressTM is a
novel seed treatment product which protects seeds during the critical
germination and emergence stage from bacterial and fungal infection. Both
products were developed against the corresponding organisms present as biofilms
as opposed to the free-floating, planktonic form.


This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024